ArticleCell metabolism2017
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Article in Cell metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic-Associated Fatty Liver Disease.Journal of clinical pharmacology · 2025Trial
- De novo lipogenesis is essential for platelet production in humans.Nature metabolism · 2020Trial
- The Biological Clock-Mitochondria Axis in the Liver: From Molecular Mechanisms to Metabolic Disease.Biology · 2026Review
- Elucidation of Mechanism of Action in Drug Invention: Using Stable Isotope Tracers to Unravel Biochemical Kinetics.Pharmacology research & perspectives · 2025Review
- A hierarchical hepatic de novo lipogenesis substrate supply network utilizing pyruvate, acetate, and ketones.Cell metabolism · 2025Article
- Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease.Frontiers in pharmacology · 2025Review
- Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances.Frontiers in endocrinology · 2025Review
- Altered drug metabolism and increased susceptibility to fatty liver disease in a mouse model of myotonic dystrophy.Nature communications · 2024Article
- Potential therapeutic strategies for MASH: from preclinical to clinical development.Life metabolism · 2024Review
- Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome.JHEP reports : innovation in hepatology · 2024Article
- The Influence of Soy Isoflavones and Soy Isoflavones with Inulin on Kidney Morphology, Fatty Acids, and Associated Parameters in Rats with and without Induced Diabetes Type 2.International journal of molecular sciences · 2024Article
- Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis.Vascular pharmacology · 2024Review
- Acyl-CoA Thioesterase 1 Contributes to Transition of Steatosis to Metabolic-Associated Steatohepatitis.International journal of hepatology · 2024Article
- GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent Manner.Cellular and molecular gastroenterology and hepatology · 2024Article
- In-depth analysis ofLiver research (Beijing, China) · 2023Review
- Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.Science advances · 2023Article
- Sex differences in paternal arsenic-induced intergenerational metabolic effects are mediated by estrogen.Cell & bioscience · 2023Article
- Acetyl-CoA metabolism in cancer.Nature reviews. Cancer · 2023Review
- Review
- FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.Scientific reports · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum for
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
28877461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.